Oral Mucosal Vaccination against HIV Infection (R21)

The summary for the Oral Mucosal Vaccination against HIV Infection (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Oral Mucosal Vaccination against HIV Infection (R21): The Exploratory/Developmental Grant (R21) mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Federal Grant Title:	Oral Mucosal Vaccination against HIV Infection (R21)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DE-08-004
Type of Funding:	Grant
CFDA Numbers:	93.121
CFDA Descriptions:	Oral Diseases and Disorders Research
Current Application Deadline:	No deadline provided
Original Application Deadline:	Aug 15, 2007
Posted Date:	Apr 03, 2007
Creation Date:	Apr 03, 2007
Archive Date:	Sep 14, 2007
Total Program Funding:	$1,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) State governments Others (see text field entitled "Additional Information on Eligibility" for clarification) Special district governments Private institutions of higher education Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses County governments
Additional Information on Eligibility: Foreign institutions are eligible to apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research ...; • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...; • NIDCR Mentoring Network to Promote a Diverse Dental, Oral and Craniofacial Research Workfo...; • Epidemiological and Behavioral Research in Oral Health; • Metagenomic Analyses of the Oral Microbiome; • Phase Iii Clinical Trials in Oral Infectious Diseases
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...